<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588640</url>
  </required_header>
  <id_info>
    <org_study_id>01-017</org_study_id>
    <nct_id>NCT00588640</nct_id>
  </id_info>
  <brief_title>Study of D-Methadone in Patients With Chronic Pain</brief_title>
  <official_title>A Phase I/II Study of D-Methadone in Patients With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safest dose of d-methadone that can be given,
      without causing severe side effects in most patients with chronic pain. Patients are being
      asked to participate in the Phase I portion of this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Who Reached a Safe Dose</measure>
    <time_frame>2 years</time_frame>
    <description>The number of patients who reached a safe and well tolerated dose of d-methadone</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pain</condition>
  <condition>Bladder Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>CNS Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Uterine Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Eye Cancer</condition>
  <condition>Otorhinolaryngologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Phase I, Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II, Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving around the clock opioid therapy-No patients were accrued to this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II, Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients not receiving around the clock opioid therapy.No patients were accrued to this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-Methadone</intervention_name>
    <description>8 subjects to receive 40 mg d-Methadone twice a day</description>
    <arm_group_label>Phase I, Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-methadone</intervention_name>
    <description>After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.</description>
    <arm_group_label>Phase II, Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.</description>
    <arm_group_label>Phase II, Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Phase I and Phase II portions of the study:

          -  18 years of age or older

          -  Chronic pain with average 24 hour intensity rated at least 3 on a verbal numerical
             scale from 0-10 during the 24 hours prior to study entry.

          -  Give informed consent to participate in this study.

          -  Karnofsky Performance Score (KPS) &gt;= to 80

          -  Negative urine pregnancy test, verified by the study nurse, at study entry (for women
             of child-bearing potential). Patients must also use a medically approved contraceptive
             method during the study period.

        Phase I only:

          -  Responsible companion living with patient during study.

        Phase II only:

          -  Group 1 -- Patients must be taking chronic opioid therapy (long acting morphine, long
             acting oxycodone, transdermal fentanyl) at a stable dose for a minimum of four days.
             The dose of as needed short acting opioid does not need to be stable.

          -  Group 2 -- Patients must not be receiving opioids and must have cancer related
             neuropathic pain secondary to post-chemotherapy peripheral neuropathy, post-radiation
             and/or post surgical plexopathy, radiculopathy or neuropathy, or post- herpetic
             neuralgia.

        Exclusion Criteria:

        Phase I and Phase II:

          -  Known hypersensitivity to methadone

          -  Patient taking methadone or with a history of methadone treatment within one month of
             study enrollment.

          -  Patient that requires changes in the dose of one of the following medications within 2
             weeks of study enrollment:

               -  Abacavir,

               -  Benzodiazepines,

               -  Carbamazepine,

               -  Efavirenz,

               -  Fluconazole,

               -  Fluvoxamine,

               -  FOS amprenavir,

               -  Fosphenytoin,

               -  Naltrexone,

               -  Nelfinavir,

               -  Nevirapine,

               -  Phenytoin,

               -  Rifampin,

               -  Rifapentine,

               -  Risperidone,

               -  Ritonavir,

               -  St. John's Wort,

               -  Zidovudine

          -  Hepatic function tests (SGOT, alkaline phosphatase, bilirubin) greater than 2 times
             the upper limit of normal or creatinine greater than 1.4 within 30 days of study
             entry.

          -  Neurologic or psychiatric disease sufficient, in the investigator's opinion, to
             compromise data collection.

          -  Women who are pregnant or nursing.

          -  Women of childbearing potential who do not agree to use a medically recognized method
             of contraception during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Moryl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2007</study_first_submitted>
  <study_first_submitted_qc>December 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2008</study_first_posted>
  <results_first_submitted>December 17, 2015</results_first_submitted>
  <results_first_submitted_qc>June 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2016</results_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>HEENT cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Eye Neoplasms</mesh_term>
    <mesh_term>Otorhinolaryngologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Receiving D-methadone 40 mg</title>
          <description>Patient Receiving D-methadone 40 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible Patient</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Receiving D-methadone 40 mg</title>
          <description>Patient Receiving D-methadone 40 mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Who Reached a Safe Dose</title>
        <description>The number of patients who reached a safe and well tolerated dose of d-methadone</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I, Cohort l</title>
            <description>oral d-methadone 40 mg
d-Methadone: 8 subjects to receive 40 mg d-Methadone twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number Who Reached a Safe Dose</title>
          <description>The number of patients who reached a safe and well tolerated dose of d-methadone</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Patients Receiving D-methadone 40 mg</title>
          <description>Patient Receiving D-methadone 40 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain - Pain NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Natalia Moryl</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-2681</phone>
      <email>moryln@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

